46,593 Shares in Insmed Incorporated (NASDAQ:INSM) Acquired by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in Insmed Incorporated (NASDAQ:INSM) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 46,593 shares of the biopharmaceutical company’s stock, valued at approximately $3,401,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Insmed by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock valued at $393,636,000 after acquiring an additional 383,714 shares during the period. Darwin Global Management Ltd. acquired a new position in shares of Insmed during the second quarter valued at about $237,076,000. Principal Financial Group Inc. raised its holdings in shares of Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after purchasing an additional 214,130 shares during the period. Clearbridge Investments LLC boosted its position in shares of Insmed by 76.8% during the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after purchasing an additional 714,539 shares in the last quarter. Finally, Hood River Capital Management LLC grew its stake in shares of Insmed by 36.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,315,392 shares of the biopharmaceutical company’s stock valued at $88,131,000 after buying an additional 352,891 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have issued reports on INSM shares. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. UBS Group upped their price objective on shares of Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Monday, September 9th. JPMorgan Chase & Co. upped their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday. Finally, StockNews.com downgraded Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Insider Transactions at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 11.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now owns 67,856 shares in the company, valued at $5,045,093.60. This represents a 29.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 78,882 shares of company stock worth $5,765,446 in the last quarter. Insiders own 4.60% of the company’s stock.

Insmed Stock Down 0.9 %

Shares of NASDAQ:INSM opened at $73.15 on Friday. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.53. The company has a market capitalization of $13.09 billion, a PE ratio of -13.18 and a beta of 1.12. The business has a fifty day moving average price of $72.04 and a two-hundred day moving average price of $66.03. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The business’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.10) EPS. Analysts forecast that Insmed Incorporated will post -5.42 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.